Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2017-06-01 Director's Dealing
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a member of the Board of Directors (Andreas Slyngborg Holst). It explicitly details the nature of the transaction (sale), the price, volume, and the identity of the person discharging managerial responsibility. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2017-06-01 English
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
Director's Dealing Classification · 100% confidence The document is a formal notification regarding a transaction in the company's shares by a person discharging managerial responsibilities (a board member). It explicitly lists the name of the individual, the nature of the transaction (sale), the financial instrument (B-shares), the price, quantity, and the date of the transaction. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2017-06-01 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse nr. 16/2017" (Company Announcement no. 16/2017) and announces a specific corporate event: the approval of the tablet vaccine ACARIZAX® in Canada. This is a specific, time-sensitive update regarding product development/regulatory status, not a comprehensive annual report (10-K), interim report (IR), or earnings release (ER). It is a general regulatory or corporate update. Since it doesn't fit the specific categories like DIRS, DIV, or MANG, and it is a formal announcement, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a Capital/Financing Update (CAP) if it were about funding, but here it is about product approval. Given the nature of a 'Selskabsmeddelelse' announcing a regulatory milestone, RNS is the most appropriate fallback for non-standard announcements.
2017-05-04 English
Regulatory Filings 2017
Regulatory Filings
2017-05-04 Danish
ALKs tabletvaccine mod hustøvmideallergi, ACARIZAX®, godkendt i Canada
Regulatory Filings Classification · 85% confidence The document is a press release via GlobeNewswire announcing regulatory approval of ALK’s ACARIZAX® tablet vaccine in Canada. It does not contain financial statements, voting results, management changes, dividends, or other report-specific content. It falls under general regulatory/compliance announcement that does not fit other categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2017-05-04 Danish
ALKs tabletvaccine mod hustøvmideallergi, ACARIZAX®, godkendt i Canada
Regulatory Filings Classification · 95% confidence The document is a company release announcing the regulatory approval of a drug (ACARIZAX) in Canada. It is a short, news-style announcement regarding corporate developments rather than a financial report, proxy, or governance document. Since it does not fit into specific categories like M&A, dividends, or director dealings, it falls under the general regulatory announcement category.
2017-05-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.